Astellas Pharma acquires Potenza Therapeutics in $404.7m deal
Japanese pharmaceutical giant Astellas Pharma has announced the acquisition of US-based Potenza Therapeutics in a significant transaction valued at up to $404.7 million. This strategic ... Read More
Alkermes expands Phase 1 trial of ALKS 4230 in combination with KEYTRUDA for advanced solid tumors
Irish biopharmaceutical company Alkermes has announced an expansion of its ongoing Phase 1 trial to evaluate the safety and anti-tumor activity of its immuno-oncology drug ... Read More
Compugen initiates Phase 1 trial of COM701 cancer immunotherapy in advanced solid tumors
Israeli pharmaceutical company Compugen has announced the commencement of a phase 1 clinical trial for its innovative cancer immunotherapy antibody, COM701, targeting patients with advanced ... Read More
Lilly completes acquisition of immuno-oncology firm Armo BioSciences
Strategic Expansion in Cancer Treatment: Eli Lilly and Company (Lilly), a leading US pharmaceutical firm, has finalized its acquisition of Armo BioSciences, a California-based immuno-oncology ... Read More
Merck to acquire Australian biotech firm Viralytics for $394m to bolster oncolytic immunotherapy treatments
Significant Acquisition in Pharma Industry: US pharmaceutical giant Merck has announced a definitive agreement to acquire Viralytics, an Australian biotech company, for AUD 502 million ... Read More
India’s CDSCO grants APAC Biotech license for immuno-oncology drug Apceden
The Central Drugs Standard Control Organization (CDSCO), India's regulatory authority, has granted a commercial license to APAC Biotech for the marketing of Apceden, a Dendritic ... Read More